{"nctId":"NCT00231816","briefTitle":"A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)","startDateStruct":{"date":"2005-09"},"conditions":["Herpes Zoster"],"count":763,"armGroups":[{"label":"Concomitant","type":"EXPERIMENTAL","interventionNames":["Biological: ZOSTAVAX™ (concomitant)","Biological: Comparator: Influenza Vaccine"]},{"label":"Nonconcomitant","type":"EXPERIMENTAL","interventionNames":["Biological: Comparator: Influenza Vaccine","Biological: ZOSTAVAX™ (Nonconcomitant)"]}],"interventions":[{"name":"ZOSTAVAX™ (concomitant)","otherNames":["V211"]},{"name":"Comparator: Influenza Vaccine","otherNames":["Fluzone, Vaxigrip"]},{"name":"ZOSTAVAX™ (Nonconcomitant)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adults 50 years of age or older\n\nExclusion Criteria:\n\n* Prior history of Herpes Zoster (shingles)\n* Prior receipt of varicella or zoster vaccine\n* Immunosuppressed","healthyVolunteers":true,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody Responses","description":"The Geometric mean titer (GMT) of the VZV glycoprotein enzyme-linked immunosorbent assay (gpELISA) antibody responses at Week 4 postvaccination in participants who received ZOSTAVAX™ concomitantly with influenza vaccine was compared to that in subjects who received influenza vaccine and ZOSTAVAX™ nonconcomitantly.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"553.5","spread":null},{"groupId":"OG001","value":"588.7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Geometric Mean Fold Rise (GMFR) in VZV gpELISA Antibody Titers From Prevaccination to 4 Weeks Postvaccination","description":"GMFR of the VZV gpELISA antibody titers from prevaccination\n\nto 4 weeks postvaccination when ZOSTAVAX™ is administered concomitantly with influenza vaccine","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Geometric Mean Titers (GMTs) of H1N1 Strain Antibody Responses at 4 Weeks Postvaccination","description":"GMT of the H1N1 strain antibody responses at 4 weeks postvaccination in participants who receive ZOSTAVAX™ concomitantly with influenza vaccine and those who receive ZOSTAVAX™ and influenza vaccine nonconcomitantly","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"122.9","spread":null},{"groupId":"OG001","value":"134.2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"GMTs of H3N2 Strain Antibody Responses at 4 Weeks Postvaccination","description":"GMT of the H3N2 strain antibody responses at 4 weeks postvaccination in participants who receive ZOSTAVAX™ concomitantly with influenza vaccine and those who receive ZOSTAVAX™ and influenza vaccine nonconcomitantly","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"162.7","spread":null},{"groupId":"OG001","value":"150.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"GMTs of B Strain Antibody Responses at 4 Weeks Postvaccination","description":"GMT of the B strain antibody responses at 4 weeks postvaccination in participants who receive ZOSTAVAX™ concomitantly with influenza vaccine and those who receive ZOSTAVAX™ and influenza vaccine nonconcomitantly","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"119.8","spread":null},{"groupId":"OG001","value":"136.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":378},"commonTop":["Injection Site Erythema (ZOSTAVAX™ injection site)","Injection Site Pain (ZOSTAVAX™ injection site)","Injection Site Pain (Influenza vaccine injection site)","Injection Site Swelling (ZOSTAVAX™ injection site)","Injection Site Erythema (Influenza vaccine injection site)"]}}}